Veru Inc

Veru Inc. reports Q4 2025 losses but stays focused on prostate cancer & urology drug development, navigating high R&D costs and regulatory hurdles.

Explore Veru Inc.’s volatile biotech outlook: negative earnings, high-risk prostate cancer pipeline, and potential upside from upcoming trials—ideal for high‑risk investors.

Veru Inc. (NASDAQ: VERU) drops below its 200‑day MA, sparking debate as analysts split between buy and sell ratings; learn what this means for investors.

Veru Inc. (Nasdaq: VRU) is a small‑cap biopharma focused on prostate cancer drugs, trading at $2.22 with a negative P/E and high volatility. Stay updated on clinical and regulatory news to assess its future upside.

Veru Inc. – a small‑cap biopharma focused on prostate cancer therapies, currently trading near $2.53 with a $40 M market cap and a negative P/E, offering high‑risk, high‑potential upside driven by upcoming clinical and partnership milestones.

Veru Inc., a biopharmaceutical company focused on prostate cancer treatment and urology specialty pharmaceuticals, faces significant financial and market challenges, including a negative price-earnings ratio and high volatility, making it a high-ris…

Veru Inc. has announced positive results from its Phase 2b study, showing that a combination of enobosarm and semaglutide is effective in treating prostate cancer supportive care with fewer side effects.

Veru Inc., a biopharmaceutical company, faces financial challenges amidst industry developments, but remains committed to developing life-saving medications for prostate cancer and urology treatments.

Veru Inc. reports promising clinical results for its prostate cancer treatment candidate, Novosarm, but faces significant financial challenges that threaten its ability to bring the treatment to market.

Veru Inc. has announced regulatory clarity for its enobosarm Phase 3 trial, a significant development that could unlock new opportunities for growth and collaboration in the biopharmaceutical industry.